Research and analysis

CHM evaluation: Transient embryonic hypoxia and teratogenicity with HPTs

MHRA assessment of transient embryonic hypoxia and teratogenicity in relation to oral hormone pregnancy tests (HPTs), as considered by the Commission on Human Medicines (CHM).

• From: Commission on Human Medicines
• Published: 1 September 2025

Documents

MHRA assessment report: Evaluation of review of transient embryonic hypoxia and teratogenicity in relation to oral hormone pregnancy tests, including Primodos

PDF, 394 KB, 23 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The UK’s Commission on Human Medicines (CHM) has considered an MHRA assessment of a new publication reviewing teratogenicity in relation to oral hormone pregnancy tests, including Primodos. The MHRA assessment is published on this page.

View the minutes of the CHM meeting held November 2024.

Published 1 September 2025